Aardvark Therapeutics (NASDAQ:AARD) Given New $4.00 Price Target at HC Wainwright

Aardvark Therapeutics (NASDAQ:AARD) had its target price reduced by HC Wainwright from $6.00 to $4.00 in a research note published on Monday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. BTIG Research reissued a “neutral” rating on shares of Aardvark Therapeutics in a research note on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Thursday, September 24th. Finally, Wall Street Zen raised shares of Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aardvark Therapeutics presently has a consensus rating of “Hold” and an average price target of $11.89.

Aardvark Therapeutics Trading Down 1.1%

Shares of NASDAQ:AARD opened at $3.74 on Monday. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.60. The stock has a market capitalization of $81.83 million, a P/E ratio of -1.17 and a beta of 3.80. The business has a 50-day moving average price of $5.52 and a two-hundred day moving average price of $5.30.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.21. As a group, equities analysts predict that Aardvark Therapeutics will post -3.17 EPS for the current year.

Insider Buying and Selling

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the transaction, the insider owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This represents a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AARD. Susquehanna International Group LLP acquired a new position in shares of Aardvark Therapeutics during the 2nd quarter worth about $138,000. J. Goldman & Co LP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at approximately $233,000. Ieq Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at approximately $221,000. BlackRock Inc. acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at approximately $1,077,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at approximately $267,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.